Showing results (61-70 of 156) with videos related to
Sort By:
Pageof 16
Diabetes|September 1, 1993
Relationship of proinsulin and insulin to cardiovascular risk factors in nondiabetic subjectsS M Haffner, L Mykkänen, M P Stern, et al.The American Journal of Physiology|July 1, 1996
Effects of circulating IGF-I on glucose and amino acid kinetics in the ovine fetusE A Liechty, D W Boyle, H Moorehead, et al.Journal of Pharmaceutical Sciences|October 9, 1999
Pharmacokinetic and glucodynamic comparisons of recombinant and animal-source glucagon after IV, IM, and SC injection in healthy volunteersC J Graf, J R Woodworth, M E Seger, et al.American Journal of Therapeutics|April 17, 2001
Cox-2-specific inhibitors: definition of a new therapeutic conceptK M Verburg, T J Maziasz, E Weiner, et al.Letters in Applied Microbiology|December 12, 2001
The effect of volatile fatty acids in acidified fermented piggery effluent on shiga-toxigenic and non-toxic resident strains of Escherichia coliI Harris, D P Henry, A FrostAmerican Journal of Therapeutics|April 17, 2001
Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patientsA Whelton, J G Fort, J A Puma, et al.Clinical Chemistry|October 1, 1992
Sensitive, specific radioimmunoassay for quantifying pergolide in plasmaR R Bowsher, J M Apathy, J A Compton, et al.Biotechnology and Applied Biochemistry|December 1, 1987
Chemical, physical, and biological characterization of a dimeric form of biosynthetic human growth hormoneG W Becker, R R Bowsher, W C Mackellar, et al.Alimentary Pharmacology & Therapeutics|September 2, 2004
Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxibJ L Goldstein, G M Eisen, N Agrawal, et al.Endocrinology|July 1, 1977
The effects of dopamine on renin release in vitroD P Henry, W Aoi, M H WeinbergerPageof 16